RECRUITINGOBSERVATIONAL
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
A Non-interventional Study and Its Clinical Relevance With Central Nervous System Metastatic Epidermal Growth Factor Receptor Mutation Positive Non-small Cell Lung Cancer
About This Trial
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients must be ≥18 years.
- Provision of fully willing to sign a consent form prior to any study specific procedures.
- Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together.
- Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC).
- According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Who Should NOT Join This Trial:
- None
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients must be ≥18 years.
* Provision of fully informed consent prior to any study specific procedures.
* Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together.
* Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC).
* According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Exclusion Criteria:
* None
Locations (1)
Hunan Cancer hospital
Changsha, Hunan, China